RNF43 and gastric cancer: In addition, a xenograft model showed that the representative FDA-approved drugs, i.e., docetaxel trihydrate, GSK-2141795 and pelitinib, exhibited obvious inhibitory effects in the RNF43 knockout of GC cells, denoting that these drugs could be novel medications for GC patients with a low expression of RNF43 [94].